Chimeric Therapeutics (ASX: CHM) shares jump on ADVENT-AML Phase 1B clinical trial progress update

February 08, 2024 01:09 PM AEDT | By Sonal Goyal

Chimeric Therapeutics (ASX: CHM) shares jump on ADVENT-AML Phase 1B clinical trial progress update — Image source: Company website

Recent News

Oil Prices Rebound Amid Fed Chair Tensions and Market Volatility

Newmont Introduces Private 5G Network at Cadia Mine for Remote Dozing...

Astute Metals Advances Red Mountain Lithium Project Through Metallurgi...

ANSTO’s Collaborative Study Advances Understanding of Methane Emission...

Highlights

First patient has received treatment in ADVENT-AML Phase 1B clinical trial.

ADVENT-AML is the first trial to assess the combination of NK cell therapy and the current standard of care for AML patients.

The trial will recruit up to 20 patients.

The clinical trial is open to enrollment at The University of Texas MD Anderson Cancer Center.

Shares of Chimeric Therapeutics Limited (ASX: CHM) surged by 13.99% to AU$0.028 apiece during the morning trading hours on 8 February 2024. The jump in CHM share price followed a company update highlighting that the first patient in the ADVENT-AML Phase 1B clinical trial has received treatment.

The trial is an investigator-initiated study, assessing CHM 0201 in combination with Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML).

Data source: company update

The ADVENT-AML Phase 1b clinical trial is the first trial to test the synergy of NK cell therapy in combination with the current standard of care for AML, Azacitidine and Venetoclax.

The trial intends to enroll up to 20 patients with newly diagnosed AML, who are not eligible for intensive chemotherapy or allogeneic stem cell transplant, following a dose confirmation cohort evaluating the safety of this combination treatments in patients with refractory or relapsed AML.

Recently, the company reported that CHM 0201 cells concluded manufacturing and release testing. They were provided to MD Anderson to assist the ADVENT-AML Phase 1B clinical trial.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.